Candesartan angiotensin-receptor blockers
systematic review meta-analysis network meta-analysis
 

CV-11974 - CV11974 - CV 11974 - candesartan - Parapres - Amias - Kenzen - Blopress - Atacand - TCV-116 - TCV 116 - candesartan cilexetil      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultAll cause deathCardiovascular death

atrial fibrillation  

CHARM (AF ancillary study), 2005     candesartanplacebosuggesting
CAPRAF (Tveit), 2007      NCTcandesartanplaceboLow risk of bias -

coronary artery disease  

SYNTAX (unprotected left main sub group), 2009     DESCABGRisk of bias suggesting0%

diabetes type 2  

SCOPE (diabetic subgroup), 2003       candesartancontrolLow risk of bias negative

heart failure  

ARCH-J, 2003     candesartanplaceboLow risk of bias -
CHARM-Alternative, 2003     candesartanplaceboLow risk of bias suggesting -13%
Mitrovic et al., 2003     candesartanplaceboLow risk of bias suggesting-37%
SPICE, 2000     candesartanplaceboLow risk of bias negative2%
STRETCH, 1999     candesartanplaceboLow risk of bias -
CHARM preserved, 2003   candesartanplaceboLow risk of bias -
CHARM-Added, 2003       candesartan+ACE inhibitorACE inhibitor onlyLow risk of bias negative
RESOLVD association, 1999     candesartan+ACE inhibitorACE inhibitor onlyExploratory negative
RESOLVD (candesartan alone), 1999     candesartanenalaprilLow risk of bias negative

heart failure with preserved LVEF  

CHARM preserved, 2003   candesartanplaceboLow risk of bias -

hypertension  

Takahashi, 2006     candesartancontrolExploratory negative-100%
E-COST-R, 2005     candesartanconventional treatmentRisk of bias negative4%4%
E-COST, 2005     candesartanconventional treatmentRisk of bias suggesting-6%∞%
HIJ-CREATE, 2009     candesartanconventional treatmentRisk of bias suggesting17%12%
SCOPE, 2003   candesartanplaceboLow risk of bias negative-3%-5%
TROPHY, 2006      NCTcandesartanplaceboLow risk of bias suggesting
HSCS, 1974   deserpidine +methylclothiazideplaceboLow risk of bias negative2%-26%
Suzuki et al, 2008     candesartanusual caresuggesting-34%-40%
HIJ-CREATE, 2009     Candesartanusual careRisk of bias -
Takahashi et al, 2006     candesartanusual caresuggesting-100%
CASE-J, 2008     candesartanamlodipineRisk of bias suggesting-15%
ALPINE, 2003   candesartanhydrochlorothiazideLow risk of bias suggesting

miscellaneous  

Takahashi, 2006     candesartancontrolExploratory negative-100%
E-COST, 2005     candesartanconventional treatmentRisk of bias suggesting-6%∞%
E-COST-R, 2005     candesartanconventional treatmentRisk of bias negative4%4%
HIJ-CREATE, 2009     candesartanconventional treatmentRisk of bias suggesting17%12%
TROPHY, 2006      NCTcandesartanplaceboLow risk of bias suggesting
SCOPE, 2003   candesartanplaceboLow risk of bias negative-3%-5%
CASE-J, 2008     candesartanamlodipineRisk of bias suggesting-15%
ALPINE, 2003   candesartanhydrochlorothiazideLow risk of bias suggesting

patients at high risk for cardiovascular events  

SCOPE, 2003   candesartanplaceboLow risk of bias negative-3%-5%

pulmonary embolism  

Tebbe, 2009     desmoteplasealteplaseExploratory -

superficial thrombophlebitis  

Andreozzi (200 vs 100), 1996   desmin 200desmin 100 -
Andreozzi (desmin SC vs 100), 1996   desmin SCdesmin 100 -

thrombosis prevention  

Ericksson, 1997     desirudinenoxaparinLow risk of bias -
REVASC, 1997     desirudinUFH -
Eriksson, 1996   desirudinUFHLow risk of bias -



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons